A
ABM Therapeutics
An innovative drug discovery and development company focusing on small molecule targeted therapy for the possible treatments of brain cancers
About ABM Therapeutics
ABM Therapeutics is an innovative drug discovery company specializing in small molecule targeted therapies for brain cancers, including glioblastoma multiforme (GBM), and brain metastasis originating from lung cancer, breast cancer, and melanoma. Founded in 2015 by a team of seasoned scientists and entrepreneurs with over 20 years of experience in neurological drug development and enterprise management, ABM Therapeutics operates in the biotechnology and pharmaceutical sectors. The company serves patients worldwide who are in need of advanced treatments for brain-related cancers. ABM Therapeutics generates revenue through the development and commercialization of its proprietary drug pipeline, which is built internally and through collaborations with Contract Research Organizations (CROs) and strategic partners. The business model focuses on both preclinical and clinical stage asset acquisitions to enhance its brain medicine research and development platform. ABM Therapeutics is committed to delivering best-in-class and first-in-class medicines to improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Huangpu, China
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 35.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2022 | $30M | $120M | Baidu Ventures · Tongde Capital · Highlight Capital · Delta Capital | — |
| SERIES AOther financing | Aug 2020 | $20M | $80M | Kaitai Capital · Pan-Lin Asset Management · Sinopharm Capital · Ming Bioventures | — |
Growth signals
Latest recorded traffic for ABM Therapeutics is 310 monthly website visits, down 27.9% over the last three months. ABM Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
- KCKaitai Capital
Pan-Lin Asset Management- SCSinopharm Capital
Ming Bioventures
China Growth Capital
Highlight Capital
Photon Fund
Baidu Ventures- TCTongde Capital
- DCDelta Capital
- SCSincere Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ABM Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ABM Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.